Latest Commercialization News

Artrya Limited has secured A$15 million through a two-tranche placement aimed at accelerating regulatory approvals and commercial rollout of its Salix® coronary artery disease diagnostic software in the US.

Tivan Limited has formalised a Resourcing Protocol Agreement with the Kimberley Land Council, setting a clear path to negotiate an Indigenous Land Use Agreement for its Speewah Project.

Mirvac's 1H25 results reveal a modest decline in EBIT and operating profit, yet the company signals strong growth prospects fueled by residential sales momentum, sustainable development, and strategic capital partnering.

AVITA Medical reported a strong 30% increase in Q4 2024 commercial revenue and amended its credit agreement with OrbiMed to adjust revenue covenants through 2026. The company is poised for significant growth with new product rollouts and expects profitability by year-end 2025.

AVITA Medical's Q4 2024 earnings reveal strong commercial growth alongside the launch of Cohealyx, a novel collagen-based skin substitute that promises to transform acute wound care.

AVITA Medical reported a robust 30% increase in Q4 2024 commercial revenue alongside key FDA clearances, setting the stage for ambitious growth in 2025.

Cochlear Limited posted a 6% increase in HY25 sales revenue driven by strong implant sales but anticipates FY25 profits at the lower end of guidance due to declining services revenue and rising cloud investments.

Cochlear Limited posted a 5% increase in sales revenue to $1.17 billion for the half year ended December 2024, driven by strong cochlear and acoustic implant growth despite a decline in Services revenue. The company anticipates FY25 underlying net profit at the lower end of guidance amid increased cloud investments and prepares for new product launches.

Embelton Limited reported a notable 25.4% decline in revenue for the half-year ended December 31, 2024, yet managed a 23% increase in net profit, underscoring effective cost controls amid a challenging construction market. The company declared an interim dividend consistent with the prior period, signaling confidence despite subdued outlook.

Micro-X Ltd has secured a $6 million contract extension from the U.S. Department of Homeland Security to develop and test additional self-screening airport security checkpoints, marking a significant step forward in its innovative security technology program.

Tivan Limited has accelerated development of its Sandover Fluorite Project in the Northern Territory, unveiling ultra high-grade assay results and a detailed exploration and approvals program targeting drilling in late 2025.

Recce Pharmaceuticals has temporarily paused trading of its securities, signaling a potentially significant development pending further disclosure.